Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Azosemide kinetics and dynamics.

D C Brater, B Day, S Anderson

    Clinical Pharmacology and Therapeutics
    |October 1, 1983
    PubMed
    Summary
    This summary is machine-generated.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Effect of Prolonged Pressure on Hemodynamics of Sacral Tissues Assessed by Diffuse Optical Imaging: A Pilot Study.

    Advances in experimental medicine and biology·2021
    Same author

    Tests of General Relativity with GW170817.

    Physical review letters·2019
    Same author

    Constraining the p-Mode-g-Mode Tidal Instability with GW170817.

    Physical review letters·2019
    Same author

    Search for Subsolar-Mass Ultracompact Binaries in Advanced LIGO's First Observing Run.

    Physical review letters·2018
    Same author

    GW170817: Measurements of Neutron Star Radii and Equation of State.

    Physical review letters·2018
    Same author

    Search for Tensor, Vector, and Scalar Polarizations in the Stochastic Gravitational-Wave Background.

    Physical review letters·2018
    Same journal

    Resolving CYP2D6 Structural Complexity with Long-Read Sequencing: Implications for Tamoxifen Precision Dosing in Thai Breast Cancer Patients.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Identification of a Functional CYP2C8 Variant Allele that Alters Splicing, Reduces Protein Expression, and Increases Drug Exposure.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Risk of Hyperkalemia in Patients with Heart Failure Treated with Spironolactone in Combination with Sacubitril/Valsartan vs. Renin-Angiotensin System Inhibitors.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Composite Endpoints in Contemporary Cardiovascular Trials: Trends in Phase 3 Trials and Key Issues in Regulatory Review.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Patient-Specific Determinants of Response to BCMA- and GPRC5D-Targeted CAR T-Cell Therapy in Multiple Myeloma: A QSP Analysis of Clinical Trial and Real-World Data.

    Clinical pharmacology and therapeutics·2026
    Same journal

    Reply to: "The Future of Clinical Pharmacology: The Right Medicine at the Right Dose for Each Patient".

    Clinical pharmacology and therapeutics·2026
    See all related articles

    Azosemide exhibits low oral bioavailability (10%) and a short elimination half-life, requiring further study for its diuretic effects. Its natriuretic response curve is distinct compared to other loop diuretics.

    Area of Science:

    • Pharmacology
    • Nephrology
    • Drug Metabolism

    Background:

    • Azosemide is a loop diuretic with potential effects on proximal tubule sodium reabsorption.
    • Understanding its pharmacokinetic and pharmacodynamic properties is crucial for clinical application.

    Purpose of the Study:

    • To investigate the kinetic and dynamic parameters of azosemide following intravenous and oral administration in healthy subjects.
    • To compare the natriuretic potency of azosemide with other loop diuretics.

    Main Methods:

    • Administration of intravenous and oral doses of azosemide to normal subjects.
    • Measurement of drug absorption and elimination half-lives.
    • Quantification of urinary excretion of unchanged azosemide.
    • Determination of the dose-response relationship for natriuretic effect.

    Related Experiment Videos

    Main Results:

    • Oral absorption showed a lag time of ~1 hour, with absorption and elimination half-lives of ~0.75 and 2-2.5 hours, respectively.
    • Only 2% of an oral dose and 20% of an intravenous dose were recovered unchanged in urine, indicating low bioavailability (~10%).
    • Azosemide demonstrated a sigmoid dose-response curve for natriuresis, with a half-maximal response dose of 9.3 ± 2.6 µg/min, significantly lower than furosemide, piretanide, and bumetanide.

    Conclusions:

    • Azosemide possesses low oral bioavailability and a relatively short elimination half-life.
    • Its natriuretic potency is considerable, suggesting potential therapeutic value despite pharmacokinetic limitations.
    • Further research is warranted to elucidate its clinical efficacy and safety profile.